Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
Posted on: Thursday, 24 September 2009, 14:04 CDT
The research demonstrated that the innate cancer killing activity of reovirus can be enhanced with a variety of commonly available therapeutic agents in models of malignant melanoma. Further, this work demonstrated that the combination of reovirus with cisplatin had the ability to nearly abrogate the production of inflammatory cytokines by the tumor cells, which is believed to augment virus replication in the tumor and improve its anti-cancer activity.
"These results provide further rationale for the Phase 2 drug combination study in patients with metastatic melanoma that was initiated today," said Dr.
About Oncolytics Biotech Inc.
Oncolytics is a
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented in "Clinical Cancer Research" with respect to REOLYSIN, the Company's expectations related to the results of trials investigating delivery of REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
Source: PR Newswire
Related Articles
- Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting
- Texas Cancer Organizations Urge State Legislature to Fully Fund the Cancer Prevention and Research Institute of Texas
- Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
- Canada Joins California in Cancer Stem Cell Research, Donates $100 Million
- Minister Clement, Governor Schwarzenegger Join Forces to Fight Cancer Through Cancer Stem Cell Research
- Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Treatment in Melanoma Animal Models at International Oncolytic Virus Conference
- U.S.-U.A.E. Partnership for Breast Cancer Awareness and Research Will Be Launched October 31
- Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Research at European National Societies of Immunology Meeting
- ProlX Pharmaceuticals Designated Corporate Partner in $5.6 Million Grant to Fund Targeted Therapy Cancer Drug Discovery Research
- Electronic Nose Capable of Sniffing Out Early Traces of Lung Cancer, Cleveland Clinic Research Shows
 |
 |
User Comments (0)
RSS Feeds